Búsqueda | Biblioteca Virtual en Salud

1.

The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.

Caldwell, G W; Ritchie, D M; Masucci, J A; Hageman, W; Yan, Z.

Curr Top Med Chem ; 1(5): 353-66, 2001 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-11899102

2.

Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.

Ho, C Y; Hageman, W E; Persico, F J.

J Med Chem ; 29(6): 1118-21, 1986 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-2872333

3.

Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid.

Greco, M N; Hageman, W E; Powell, E T; Tighe, J J; Persico, F J.

J Med Chem ; 35(17): 3180-3, 1992 Aug 21.

Artículo en Inglés | MEDLINE | ID: mdl-1324317

4.

Cardiac-slowing amidines containing the 3-thioindone group. Potential antianginal agents.

Zelesko, M J; McComsey, D F; Hageman, W E; Nortey, S O; Baker, C A; Maryanoff, B E.

J Med Chem ; 26(2): 230-7, 1983 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-6687480

5.

Synthesis and 5-lipoxygenase inhibitory activities of some novel 2-substituted 5-benzofuran hydroxamic acids.

Ohemeng, K A; Appollina, M A; Nguyen, V N; Schwender, C F; Singer, M; Steber, M; Ansell, J; Argentieri, D; Hageman, W.

J Med Chem ; 37(21): 3663-7, 1994 Oct 14.

Artículo en Inglés | MEDLINE | ID: mdl-7932593

6.

Cardiovascular profile of 5-methyl-2-phenyl-4-imidazole-acetonitrile (MCN-2378), a cerebral vasodilator.

Hageman, W E; Pruss, T P.

Eur J Pharmacol ; 30(1): 100-6, 1975 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-1122930

7.

Inhibition of leukotriene and thromboxane biosynthesis by a 9-(4-chlorophenyl) analogue of arachidonic acid.

Ho, C Y; Hageman, W E; Mohrbacher, R J; End, D W.

J Pharm Sci ; 77(2): 149-52, 1988 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-3129546

8.

A further refinement of the reliable change (RC) index by improving the pre-post difference score: introducing RCID.

Hageman, W J; Arrindell, W A.

Behav Res Ther ; 31(7): 693-700, 1993 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-8216170

9.

Establishing clinically significant change: increment of precision and the distinction between individual and group level of analysis.

Hageman, W J; Arrindell, W A.

Behav Res Ther ; 37(12): 1169-93, 1999 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-10596464

10.

Clinically significant and practical! Enhancing precision does make a difference. Reply to McGlinchey and Jacobson, Hsu, and Speer.

Hageman, W J; Arrindell, W A.

Behav Res Ther ; 37(12): 1219-33, 1999 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-10596468

11.

A practical rationale for trustee education.

Hageman, W M.

Trustee ; 43(9): 10-1, 1990 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-10106224

12.

A cost containment success story.

Hart, J D; Hageman, W.

Trustee ; 31(9): 59-60, 62, 64, 1978 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-10238293

13.

Governance and management: where do you draw the line?

Umbdenstock, R J; Hageman, W M.

Trustee ; 37(4): 19-24, 1984 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-10266002

14.

Layers of leadership. The challenges of collaborative governance.

Hageman, W M; Bogue, R J.

Trustee ; 51(8): 18-20, 22, 24, 1998 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-10185656

15.

Interaction of vasoactive agents and micro-emboli on the pulmonary circulation.

Hageman, W E; Wentling, D G; Pruss, T P.

Eur J Pharmacol ; 22(3): 295-303, 1973 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-4354578

16.

Action of angiotensin II upon renal vascular resistance.

Hageman, W E; Buckley, J P.

J Pharm Sci ; 56(7): 876-81, 1967 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-4291937

17.

Organizing and focusing the board's work: keys to effectiveness.

Hageman, W M; Umbdenstock, R J.

Front Health Serv Manage ; 6(3): 29-33, 46, 1990.

Artículo en Inglés | MEDLINE | ID: mdl-10103523

18.

Streamlining your corporate structure: a new concept in governance.

Hart, J D; Hageman, W M.

Healthc Exec ; 4(3): 25-6, 1989.

Artículo en Inglés | MEDLINE | ID: mdl-10303609

19.

Diversity on the board.

Hageman, W.

Trustee ; 48(2): 22-3, 1995 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-10140572

20.

Targeting the board's strengths and weaknesses.

Hageman, W M.

Trustee ; 40(10): 28, 1987 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-10284775

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.

Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.

Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid.

Cardiac-slowing amidines containing the 3-thioindone group. Potential antianginal agents.

Synthesis and 5-lipoxygenase inhibitory activities of some novel 2-substituted 5-benzofuran hydroxamic acids.

Cardiovascular profile of 5-methyl-2-phenyl-4-imidazole-acetonitrile (MCN-2378), a cerebral vasodilator.

Inhibition of leukotriene and thromboxane biosynthesis by a 9-(4-chlorophenyl) analogue of arachidonic acid.

A further refinement of the reliable change (RC) index by improving the pre-post difference score: introducing RCID.

Establishing clinically significant change: increment of precision and the distinction between individual and group level of analysis.

Clinically significant and practical! Enhancing precision does make a difference. Reply to McGlinchey and Jacobson, Hsu, and Speer.

A practical rationale for trustee education.

A cost containment success story.

Governance and management: where do you draw the line?

Layers of leadership. The challenges of collaborative governance.

Interaction of vasoactive agents and micro-emboli on the pulmonary circulation.

Action of angiotensin II upon renal vascular resistance.

Organizing and focusing the board's work: keys to effectiveness.

Streamlining your corporate structure: a new concept in governance.

Diversity on the board.

Targeting the board's strengths and weaknesses.